Articles

In an op-ed for The Hill, Professor Neeraj Sood writes that until legislators and regulators understand where the profits are flowing in the prescription drug distribution system, bills to control prices risk being ineffective.

Summer’s story reveals the weaknesses in San Francisco’s mental illness and addiction treatment system.

Since the 1990s, children, adolescents, and young adults have also experienced dramatic increases in exposure to and harms from prescription opioids.

The CBO estimated that the Pelosi drug pricing reform legislation proposed would save Medicare $345 billion over seven years. It failed to look at the long-term effect on new drug discovery and the impact on population health.

Outrage about the rising prices of prescription drugs has put cancer drugs in the spotlight. But there’s an important question that needs to be asked: What is the best pricing metric to use for them?

Helping people benefit from the programs for which they are eligible could have a significant impact on the share of Americans with health coverage, possibly making the idea of automatic enrollment into coverage attractive across the political spectrum.

Do the clinical gains offered by these drugs in treating specific cancer indications justify the price increases? Schaeffer Center researchers Alice Chen and Dana Goldman explore how we might measure the value of these drugs.

In a panel discussion, Schaeffer experts outline policy approaches to improve the current healthcare system, following keynote remarks by California Attorney General Xavier Becerra.

This blog presents new evidence on observed changes in provider network breadth after the implementation of California’s 2017 law.

Less than 5 percent of state drug pricing laws passed between 2015 and 2018 will provide new information about pricing within the pharmaceutical distribution system.